Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million

SNOA•2026-08-06

Q1 revenue and earnings improve

Sonoma Pharmaceuticals posted a net loss of USD 330,000 for the quarter ended June 30, 2026, narrowing from USD 1.24 million.

Revenue rose 60% to USD 6.41 million, led by the United States where revenue more than doubled to USD 2.43 million.

Gross profit and cash position strengthen

Gross profit climbed 76% to USD 2.58 million; gross margin widened 4 percentage points to 40% on manufacturing improvements and customer mix.

Cash and cash equivalents increased to USD 5.34 million at June 30 from USD 2.4 million at March 31, helped by USD 3.45 million in financing cash flow.

Sources

Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million

Sec

Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million

Q1 revenue and earnings improve

Gross profit and cash position strengthen

Related News

Planet Labs schedules fiscal Q2 2027 results release and conference call

MIND CTI Q2 FY26 net income rises to $0.8 million; revenue falls to $4.6 million

Qatar's Ooredoo leads $800 million investment in AI platform Zankore

Sources

Sonoma Pharma FY27 Q1 net loss narrows 73.41% to USD 330,000; revenue rises 60% to USD 6.41 million

Keurig Dr Pepper reaffirms forecast on strong soda, energy drink demand

Knight-Swift declares quarterly cash dividend of $0.20 per share